176. Dare to Commercialize: Damien Perriman’s eXoZymes Playbook

Episode notes

Damien Perriman, Chief Commercial Officer of eXoZymes and the commercial lead behind the NCTx spinout, breaks down why cell-free biomanufacturing changes the rules for scaling nature’s rare molecules. Damien explains why the team spun NCTX out as a separate commercial vehicle, what it means to successfully transfer a process to a partner manufacturer (including a milestone Cayman validation), and why NCT (n-trans-caffeoyl tyramine), a trace compound found in peppercorns and hemp seed husks, has drawn so much attention as the only known agonist of HNF4A, a metabolic “switch” tied to mitochondrial function. The conversation also covers the logic behind launching first in supplements, how to build credibility in a crowded category through safety and product consistency, how regulatory timelines shape strategy, and why industrial biotech needs to move from platform-first stories to molecule-led business cases that match real market demand. Grow Everything brings the bioeconomy to life. Hosts Karl Schmieder and Erum Azeez Khan share stories and interview the leaders and influencers changing the world by growing everything. Biology is the oldest technology. And it can be engineered.

• 186. N.Y. Tech Week Live Demo: Engineering the Future of Manufacturing with Roebling's Brentan Alexander52 / 100
• 185. Brick Happens: Chris Maurer of Redhouse Studio Redesigns Remote Living for Earth and Mars55 / 100
• 184. The Multiverse of Microbes: Henry Lee on Building Cultivarium and Training with Titans45 / 100
• 183. The American Biotech Blueprint: Senator Todd Young on Biodiversity as National Security
• 182. SynBioBeta 2026 Recap, It's Biologist Approved